er, and advanced or 
unresectable pelvic tumors2. Moreover, in the 
United States, major insurance providers such 
as AETNA, also expanded their authorized 
indications to now include esophageal cancer 
and primary central nervous system tumors, as 
well as malignancies in patients under 21, amongst others3. There are a range of ongoing clinical studies 
using PT, including in head and neck, esophageal, lung and breast cancer. Two Phase 
3 trials4 in head and neck cancer have 
completed patient recruitment in 2023, alongside 
a multi-center trial5 for lung cancer.